U.S. markets closed
  • S&P Futures

    4,466.00
    +20.25 (+0.46%)
     
  • Dow Futures

    34,845.00
    +171.00 (+0.49%)
     
  • Nasdaq Futures

    15,389.75
    +71.00 (+0.46%)
     
  • Russell 2000 Futures

    2,258.00
    +14.00 (+0.62%)
     
  • Crude Oil

    75.23
    +1.25 (+1.69%)
     
  • Gold

    1,759.10
    +7.40 (+0.42%)
     
  • Silver

    22.66
    +0.23 (+1.03%)
     
  • EUR/USD

    1.1727
    +0.0010 (+0.08%)
     
  • 10-Yr Bond

    1.4600
    +0.0500 (+3.55%)
     
  • Vix

    17.75
    -0.88 (-4.72%)
     
  • GBP/USD

    1.3679
    -0.0002 (-0.01%)
     
  • USD/JPY

    110.6400
    -0.0450 (-0.04%)
     
  • BTC-USD

    44,237.32
    +1,946.29 (+4.60%)
     
  • CMC Crypto 200

    1,105.44
    +2.38 (+0.22%)
     
  • FTSE 100

    7,051.48
    -26.87 (-0.38%)
     
  • Nikkei 225

    30,344.76
    +95.95 (+0.32%)
     

What Does Globus Medical, Inc.'s (NYSE:GMED) Share Price Indicate?

  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Globus Medical, Inc. (NYSE:GMED), might not be a large cap stock, but it received a lot of attention from a substantial price increase on the NYSE over the last few months. With many analysts covering the mid-cap stock, we may expect any price-sensitive announcements have already been factored into the stock’s share price. However, could the stock still be trading at a relatively cheap price? Let’s take a look at Globus Medical’s outlook and value based on the most recent financial data to see if the opportunity still exists.

View our latest analysis for Globus Medical

What's the opportunity in Globus Medical?

Good news, investors! Globus Medical is still a bargain right now. My valuation model shows that the intrinsic value for the stock is $86.67, which is above what the market is valuing the company at the moment. This indicates a potential opportunity to buy low. However, given that Globus Medical’s share is fairly volatile (i.e. its price movements are magnified relative to the rest of the market) this could mean the price can sink lower, giving us another chance to buy in the future. This is based on its high beta, which is a good indicator for share price volatility.

What does the future of Globus Medical look like?

earnings-and-revenue-growth
earnings-and-revenue-growth

Investors looking for growth in their portfolio may want to consider the prospects of a company before buying its shares. Buying a great company with a robust outlook at a cheap price is always a good investment, so let’s also take a look at the company's future expectations. Globus Medical's earnings over the next few years are expected to double, indicating a very optimistic future ahead. This should lead to stronger cash flows, feeding into a higher share value.

What this means for you:

Are you a shareholder? Since GMED is currently undervalued, it may be a great time to accumulate more of your holdings in the stock. With a positive outlook on the horizon, it seems like this growth has not yet been fully factored into the share price. However, there are also other factors such as capital structure to consider, which could explain the current undervaluation.

Are you a potential investor? If you’ve been keeping an eye on GMED for a while, now might be the time to make a leap. Its buoyant future outlook isn’t fully reflected in the current share price yet, which means it’s not too late to buy GMED. But before you make any investment decisions, consider other factors such as the strength of its balance sheet, in order to make a well-informed investment decision.

If you'd like to know more about Globus Medical as a business, it's important to be aware of any risks it's facing. For example, we've discovered 1 warning sign that you should run your eye over to get a better picture of Globus Medical.

If you are no longer interested in Globus Medical, you can use our free platform to see our list of over 50 other stocks with a high growth potential.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.